NCT02525692 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Patients with histologically confirmed WHO Grade IV glioblastoma with any number of recurrences. Patients received 625 mg oral ONC201 once every 3 weeks.
- id
- FG000
- title
- Arm A
- description
- Patients with first recurrence of histologically confirmed WHO Grade IV glioma. Patients received 625 mg oral ONC201 once every week (Days 1, 8, and 15 of each cycle).
- id
- FG001
- title
- Arm B
- description
- Patients with clinical and/or radiographic evidence of first recurrence of histologically confirmed WHO Grade IV glioblastoma and were eligible for salvage surgical resection. Patients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.
- id
- FG002
- title
- Arm C
- description
- Patients with confirmed WHO Grade IV glioma with H3 K27M mutation (any number of recurrences were allowed). Patients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).
- id
- FG003
- title
- Arm D
- description
- Patients with clinical and/or radiographic evidence of midline glioma (recurrent disease was not required) and were eligible for salvage surgical resection. Patients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.
- id
- FG004
- title
- Arm E
- description
- Patients with diffuse midline glioma involving the brainstem, thalamus, or spinal cord, without H3 K27M mutation or with unknown H3 mutation status. Patients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).
- id
- FG005
- title
- Arm F
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 18
- group Id
- FG002
- num Subjects
- 7
- group Id
- FG003
- num Subjects
- 20
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 6
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Lost to Follow-up
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 7
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Patients with histologically confirmed WHO Grade IV glioblastoma with any number of recurrences. Patients received 625 mg oral ONC201 once every 3 weeks.
- id
- FG000
- title
- Arm A
- description
- Patients with first recurrence of histologically confirmed WHO Grade IV glioma. Patients received 625 mg oral ONC201 once every week (Days 1, 8, and 15 of each cycle).
- id
- FG001
- title
- Arm B
- description
- Patients with clinical and/or radiographic evidence of first recurrence of histologically confirmed WHO Grade IV glioblastoma and were eligible for salvage surgical resection. Patients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.
- id
- FG002
- title
- Arm C
- description
- Patients with confirmed WHO Grade IV glioma with H3 K27M mutation (any number of recurrences were allowed). Patients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).
- id
- FG003
- title
- Arm D
- description
- Patients with clinical and/or radiographic evidence of midline glioma (recurrent disease was not required) and were eligible for salvage surgical resection. Patients received 625 mg oral ONC201 once weekly (Days 1, 8 and 15 of each cycle). Surgical resection was performed approximately 24 hours after at least the second dose of ONC201.
- id
- FG004
- title
- Arm E
- description
- Patients with diffuse midline glioma involving the brainstem, thalamus, or spinal cord, without H3 K27M mutation or with unknown H3 mutation status. Patients received 625 mg oral ONC201 once weekly (Days 1, 8, and 15 of each cycle).
- id
- FG005
- title
- Arm F
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 1
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 18
- group Id
- FG002
- num Subjects
- 7
- group Id
- FG003
- num Subjects
- 20
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 6
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 5
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- Lost to Follow-up
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 7
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 17
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 30
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 7
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle